These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16778204)

  • 1. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
    Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
    Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
    Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
    J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
    Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
    Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of RET with multiple endocrine neoplasia type 2.
    Zhang M; Liu Y; Fu J; Hu Y; Sun Z
    J Cancer Res Ther; 2017; 13(5):823-828. PubMed ID: 29237911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
    Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
    Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
    Vidal M; Wells S; Ryan A; Cagan R
    Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
    Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
    Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.